Tebotelimab

特泊利单抗

Report date: 2022/03/23 10:30:45

Base Information

Drug NameTebotelimab
Drug Alias NameAnti-PD-1PD-1 x LAG-3 bispecific DART moleculeAnti-LAG-3 bispecific DART proteinPD-1 X LAG-3MGD-013
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitorsProgrammed cell death protein 1 blockers
TargetsLymphocyte activation gene 3 proteinProgrammed cell death protein 1
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursNeoplasm Metastasis +[20] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesUkraine +[10] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMacrogenics Inc
China Registration ClassN/A

Develop Information

Active CompaniesZai Lab (Shanghai) Co LtdMacrogenics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[12] 
Inactive IndicationsGastroesophageal Junction NeoplasmsNeoplasm MetastasisEndometrial Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A